Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Current Deferred Revenue (2016 - 2025)

China Pharma Holdings' Current Deferred Revenue history spans 16 years, with the latest figure at $111580.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 31.21% year-over-year to $111580.0; the TTM value through Dec 2025 reached $111580.0, down 31.21%, while the annual FY2025 figure was $111580.0, 31.21% down from the prior year.
  • Current Deferred Revenue reached $111580.0 in Q4 2025 per CPHI's latest filing, down from $120912.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $572013.0 in Q1 2021 to a low of $24920.0 in Q3 2024.
  • Average Current Deferred Revenue over 5 years is $194606.1, with a median of $128505.5 recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: tumbled 85.52% in 2024, then skyrocketed 385.2% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $210028.0 in 2021, then soared by 147.73% to $520295.0 in 2022, then plummeted by 82.6% to $90507.0 in 2023, then skyrocketed by 79.22% to $162208.0 in 2024, then plummeted by 31.21% to $111580.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Current Deferred Revenue are $111580.0 (Q4 2025), $120912.0 (Q3 2025), and $77683.0 (Q2 2025).